TPEx
Every company in the roster listed on TPEx.
Every company in the roster listed on TPEx.
10 of 10 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Alar Pharmaceuticals6785 · TPEx | 1 asset: 1 Ph 1 | ALA-3000Phase 1 · Major Depressive DisorderPartial signal | None on record | — | — | — | — |
Anbogen Therapeutics, Inc.7784 · TPEx | 1 asset: 1 Ph 2 | GozanertinibPhase 1/2 · Non-Small Cell Lung Cancer | Nov 2026Gozanertinib · Phase 1/2 | — | — | — | — |
AP Biosciences Inc.6945 · TPEx | 2 assets: 2 Ph 2 | B1962Phase 2 · Non-Small Cell Lung Cancer | Dec 2026AP203 · Phase 1/2 | — | — | — | — |
Foresee Pharmaceuticals6576 · TPEx | 1 asset: 1 Ph 2 | MirivadelgatPhase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | Feb 2028Mirivadelgat · Phase 2 | — | — | — | — |
Genovate Biotechnology4130 · TPEx | 2 assets: 2 Ph 3 | PrusogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Oneness Biotech4743 · TPEx | 1 asset: 1 Ph 2 | FB825Phase 2 · Atopic DermatitisWeak signal | 31 May 2027FB825 · Phase 2 | — | — | — | — |
Orient EuroPharma4120 · TPEx | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
PharmaEngine4162 · TPEx | 1 asset: 1 Ph 1 | PEP07Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026PEP07 · Phase 1 | — | — | — | — |
Pharmosa Biopharm Inc.6875 · TPEx | 1 asset: 1 Ph 3 | Treprostinil (L606)Phase 3 · Pulmonary Arterial Hypertension | Jul 2029Treprostinil (L606) · Phase 3 | — | — | — | — |
TaiMed Biologics4147 · TPEx | 2 assets: 1 approved, 1 Ph 2 | TMB-365 / TMB-380Phase 2 · HIV | May 2027TMB-365 / TMB-380 · Phase 2 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.